1051 ET - There will be a debate around how conservative Doximity's guidance is until the company's typical upselling season kicks off in August, JPMorgan analysts say in a research note. At that point, Doximity will have better clarity into how the budgets of its pharmaceutical clients are shaping up, the analysts say. As of right now, the company's outlook assumes some weakness in cross-selling and upselling, they say. But management says it hasn't seen any indications yet of its market slowing, and that Doximity faces less risk than it used to now that just under 70% of the year's revenue is already under contract, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
May 16, 2025 10:51 ET (14:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.